79722-21-7

Basic information

• Product Name: TERT-BUTYL N-(BENZYLOXY)CARBAMATE
• Synonyms: LABOTEST-BB LT00452293;TERT-BUTYL N-(BENZYLOXY)CARBAMATE;N-(BENZYLOXY)CARBAMIC ACID TERT-BUTYL ESTER;TERT-BUTYL BENZYLOXYCARBAMATE;tert-Butyl N-(benzyloxy)carbamate ,98%;O-Benzylhydroxylamine, N-BOC protected, tert-Butyl (phenylmethoxy)carbamate;tert-Butyl (benzyloxy)carbamate 99%;N-Boc-Bn Tert-butyl n-(benzyloxy)carbamate
• CAS NO: 79722-21-7
• Molecular Formula: C₁₂H₁₇NO₃
• Molecular Weight: 223.27
• EINECS: 1533716-785-6
• Product Categories: Hydroxylamines;Hydroxylamines (N-Substituted);Hydroxylamines (O-Substituted);Nitrogen Compounds;Organic Building Blocks;Protected Amines
• Mol File: 79722-21-7.mol
• Article Data: 33

Chemical Properties

• Melting Point: 45-47 °C(lit.)
• Appearance: /
• Density: 1.078±0.06 g/cm3 (20 ºC 760 Torr)
• Refractive Index: 1.505
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• CAS DataBase Reference: TERT-BUTYL N-(BENZYLOXY)CARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL N-(BENZYLOXY)CARBAMATE(79722-21-7)
• EPA Substance Registry System: TERT-BUTYL N-(BENZYLOXY)CARBAMATE(79722-21-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 79722-21-7(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Uses

Different sources of media describe the Uses of 79722-21-7 differently. You can refer to the following data:
1. tert-Butyl N-(benzyloxy)carbamate was used in the preparation of seven-membered cyclic hydroxamic acids. It may be used in the synthesis of 2-(N-formyl-N-hydroxyamino) ethylphosphonate (IPP).
2. tert-Butyl N-(Benzyloxy)carbamate has been used in the synthesis of Deferoxamine Mesylate (D228980), an iron chelating agent used in therapy for patients with sickle cell diseases and iron overload. Studies suggest that it can exert potential antioxidant neuroprotective effects in stroke patients

General Description

tert-Butyl N-(benzyloxy)carbamate (tert-butyl benzyloxycarbamate), a protected hydroxylamine, is an N-alkyl-N-benzyloxy carbamate. Its C-N cross coupling reaction with fluorescein ditriflate has been reported. It participates in facile intramolecular cyclization with various carbon nucleophiles to afford functionalized 5- and 6-membered protected cyclic hydroxamic acids.

InChI:InChI=1/C12H17NO3/c1-12(2,3)16-11(14)13-15-9-10-7-5-4-6-8-10/h4-8H,9H2,1-3H3,(H,13,14)

Upstream product

• 36016-38-3 tert-Butyl N-hydroxycarbamate 
• 100-39-0 benzyl bromide 
• 622-33-3 N-benzyloxyamine 
• 16653-19-3 N-(benzyloxy)phthalimide 
• 34619-03-9 tert-butyldicarbonate 
• 2687-43-6 O-benzylhydoxylamine hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 497-19-8 sodium carbonate 
• 219547-77-0 t-butyl 3-(trichloromethyl)-1,2-oxaziridine-2-carboxylate 
• 100-51-6 benzyl alcohol 
• 29601-98-7 N-benzylhydroxylamine hydrochloride 

Downstream Products

• 79722-22-8 N-methyl-2-{[(benzyloxy)carbamoyl]oxy}-2-methylpropylidyne 
• 312529-09-2 tert-butyl (benzyloxy) (phenethyl)carbamate 
• 489452-95-1 4-[N-(tert-butyloxycarbonyl)benzyloxyamino]butyronitrile 
• 902526-60-7 [3-(N-benzyloxy-N-tert-butoxycarbonylamino)-1-(2-fluorophenyl)-propyl]-phosphonic acid diethyl ester 
• 902526-61-8 [3-(N-benzyloxy-N-tert-butoxycarbonylamino)-1-(2,6-dimethylphenyl)-propyl]-phosphonic acid diethyl ester 
• 902526-59-4 [3-(N-benzyloxy-N-tert-butoxycarbonylamino)-1-(3,4-difluorophenyl)-propyl]-phosphonic acid diethyl ester 
• 887232-72-6 dibenzyl (1R,2S)-2-[N-(benzyloxy),N-(tert-butoxycarbonyl)aminomethyl]cyclopropylphosphonate 
• 950846-93-2 {2-[(benzyloxy-tert-butyloxycarbonyl-amino)-methyl]-phenyl}-phosphonic acid diethyl ester 
• 1010101-48-0 N-tert-butoxycarbonyl-N-phenyl-O-benzylhydroxylamine 
• 1010101-43-5 N-Boc-N-(4-fluorophenyl)-O-benzylhydroxylamine 
• 1010101-44-6 N-Boc-N-(4-tolyl)-O-benzylhydroxylamine 
• 1010101-45-7 N-Boc-N-(4-methoxyphenyl)-O-benzylhydroxylamine 
• 1010101-46-8 N-Boc-N-(4-cyanophenyl)-O-benzylhydroxylamine 
• 1172627-15-4 C₁₆H₂₃NO₄ 

Relevant articles and documents

Oxa Analogues of Nexturastat A Demonstrate Improved HDAC6 Selectivity and Superior Antileukaemia Activity

The acetylome is important for maintaining the homeostasis of cells. Abnormal changes can result in the pathogenesis of immunological or neurological diseases, and degeneration can promote the manifestation of cancer. In particular, pharmacological interv

Thermodynamic Stability and Speciation of Ga(III) and Zr(IV) Complexes with High-Denticity Hydroxamate Chelators

Increasing attention has been recently devoted to 89Zr(IV) and 68Ga(III) radionuclides, due to their favorable decay characteristics for positron emission tomography (PET). In the present paper, a deep investigation is presented on Ga(III) and Zr(IV) comp

Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, incurable cancer with a 20% 1 year survival rate. While standard-of-care therapy can prolong life in a small fraction of cases, PDAC is inherently resistant to current treatments, and novel therapies are urgently required. Histone deacetylase (HDAC) inhibitors are effective in killing pancreatic cancer cells in in vitro PDAC studies, and although there are a few clinical studies investigating combination therapy including HDAC inhibitors, no HDAC drug or combination therapy with an HDAC drug has been approved for the treatment of PDAC. We developed an inhibitor of HDACs, AES-135, that exhibits nanomolar inhibitory activity against HDAC3, HDAC6, and HDAC11 in biochemical assays. In a three-dimensional coculture model, AES-135 kills low-passage patient-derived tumor spheroids selectively over surrounding cancer-associated fibroblasts and has excellent pharmacokinetic properties in vivo. In an orthotopic murine model of pancreatic cancer, AES-135 prolongs survival significantly, therefore representing a candidate for further preclinical testing.